• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.

作者信息

Danese Silvio, Mocciaro Filippo, Guidi Luisa, Scribano Maria Lia, Comberlato Michele, Annese Vito, Colombo Elisabetta, Stefanelli Tommaso, Marzo Manuela, Vangeli Marcello, Pulitano' Raffaella, Manca Aldo, Armuzzi Alessandro, Malesci Alberto, Prantera Cosimo, Cottone Mario

出版信息

Inflamm Bowel Dis. 2008 Aug;14(8):1168-70. doi: 10.1002/ibd.20426.

DOI:10.1002/ibd.20426
PMID:18357580
Abstract
摘要

相似文献

1
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
Inflamm Bowel Dis. 2008 Aug;14(8):1168-70. doi: 10.1002/ibd.20426.
2
Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.赛妥珠单抗聚乙二醇化：新药。作为克罗恩病的最后治疗手段：继续使用其他肿瘤坏死因子α抑制剂。
Prescrire Int. 2009 Jun;18(101):108-10.
3
Maintenance therapy with certolizumab pegol for Crohn's disease.聚乙二醇化赛妥珠单抗用于克罗恩病的维持治疗。
N Engl J Med. 2007 Jul 19;357(3):239-50. doi: 10.1056/NEJMoa062897.
4
Another anti-TNF therapy for patients with Crohn's disease.
Inflamm Bowel Dis. 2008 Mar;14(3):425-7. doi: 10.1002/ibd.20338.
5
Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.优化肿瘤坏死因子抑制剂在克罗恩病中的应用：一种实用方法。
Drugs. 2010;70(2):109-20. doi: 10.2165/11533700-000000000-00000.
6
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.培塞丽珠单抗持续治疗可使克罗恩病患者的缓解期长达 18 个月。
Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1.
7
Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease.信函：分剂量聚乙二醇化赛妥珠单抗治疗克罗恩病的疗效
Aliment Pharmacol Ther. 2013 Dec;38(11-12):1412. doi: 10.1111/apt.12506.
8
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.临床试验：先前使用英夫利昔单抗治疗对培塞利珠单抗维持治疗克罗恩病的临床应答的影响。
Aliment Pharmacol Ther. 2010 Aug;32(3):384-93. doi: 10.1111/j.1365-2036.2010.04360.x. Epub 2010 May 18.
9
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.短病程克罗恩病患者皮下注射培塞丽珠单抗的应答率和缓解率提高：PRECiSE 2 随机维持试验数据的分析。
Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78. Epub 2010 Mar 16.
10
Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".用于克罗恩病的抗肿瘤坏死因子-α治疗：“三人行”。 （此翻译保留了原文的双引号内容，从字面上看比较怪异，推测原文可能是一种比喻或特定表述，在医学语境下也许有其特定含义，仅从翻译角度呈现。）
Curr Drug Targets. 2010 Feb;11(2):136-7. doi: 10.2174/138945010790309911.

引用本文的文献

1
Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.炎症性肠病的诊断和管理进展：挑战和不确定性。
Saudi J Gastroenterol. 2014 Mar-Apr;20(2):81-101. doi: 10.4103/1319-3767.129473.
2
New biologics in the management of Crohn's disease: focus on certolizumab pegol.克罗恩病治疗中的新型生物制剂：聚焦聚乙二醇化赛妥珠单抗。
Clin Exp Gastroenterol. 2009;2:61-8. Epub 2009 Jun 24.
3
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.单克隆抗体疗法治疗炎症性肠病的现状
Expert Rev Clin Immunol. 2010 Jul;6(4):607-20. doi: 10.1586/eci.10.45.